



4th September 2015

Aurobindo Pharma receives USFDA Approval for Telmisartan Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Telmisartan Tablets USP 20mg, 40mg, and 80mg (ANDA 206511).

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Micardis® Tablets of Boehringer Ingelheim Pharmaceuticals, Inc.

Telmisartan Tablets are indicated in the treatment of essential hypertension and has an estimated market size of US\$92 Million for the twelve months ending July 2015 according to IMS.

This is the 46th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 211 ANDA approvals (183 Final approvals including 9 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com

Website : www.aurobindo.com

Corporate Off: WaterMark Building, Level-1
Plot No.11, Survey No. 9
Kondapur, Hitech City, Hyderabad

Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad